Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals

Journal of Neuroscience Research

Volumn 43, Issue 4, 1996, Pages 482-489

  Zhang, X ^a   Zuo, D M ^a   Davis, B A ^a   Boulton, A A ^a   Yu, P H ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Deprenyl; DSP 4; Hippocampus; Monoamine oxidase B inhibitors; Neuroprotection; Neurotoxicity; Noradrenaline

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE BETA MONOOXYGENASE; NEUROTOXIN; NORADRENALIN; SELEGILINE;

AGING; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM CORTEX; ENZYME ACTIVITY; ENZYME INHIBITION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; AXONS; BENZYLAMINES; IMMUNOHISTOCHEMISTRY; MALE; MONOAMINE OXIDASE INHIBITORS; NERVE DEGENERATION; NERVE ENDINGS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NOREPINEPHRINE; PROPYLAMINES; RATS; RATS, WISTAR; REFERENCE VALUES; SELEGILINE; SENSITIVITY AND SPECIFICITY;

EID: 0029938017     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19960215)43:4<482::AID-JNR9>3.0.CO;2-B     Document Type: Article

References (54)

1. Adolfsson R, Gottfries CG, Roos BE (1979): Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135:216-223.
2. Ansari KS, Yu PH, Knick TX, Tatton WG (1993): Death of axotomized immature rat facial motoneurons: stereospecific rescue by R(-)-deprenyl independently of MAO inhibition. J Neurosci 13:4042-4053.
3. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983): Deprenyl leads to prolongation of 1-Dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 19:170-176.
4. Bondareff W, Mountjoy CQ, Roth M (1982): Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32:164-168.
5. Chan-Palay V (1991): Alterations in the locus coeruleus in dementia of Alzheimer's and Parkinson's disease. In Barnes CD, Pompeiano O (eds): ''Progress in Brain Research. Vol 88, Neurobiology of the Locus Coeruleus." Amsterdam: Elsevier Biomedical Press, pp 625-630.
6. Chan-Palay V, Asen E (1989a): Quantification of catecholamine neurons in the locus coeruleus in human brains of normal young and old adults and in depression. J Comp Neurol 287:357-372.
7. Chan-Palay V, Asen E (1989b): Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287:373-392.
8. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Linson BE (1981): Reduced dopamine-β-hydroxylase activity in Alzheimer's disease. Br Med J 282:93-94.
9. Fang J, Yu PH (1994): Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology (in press).
10. Fety R, Misere V, Lambas-Senas L, Renaud B (1986): Central and peripheral changes in catecholamine-synthesizing enzyme activities after systemic administration of the neurotoxin DSP-4. Eur J Pharmacol 124:197-202.
11. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980): The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1-20.
12. Finnegan KT, Skratt JS, Irwin I, DeLanney LE, Langston JW (1990): Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B Eur J Pharmacol 184:119-126.
13. Fritschy J-M, Grzanna R (1989): Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30:181-197.
14. Fritschy J-M, Grzanna R (1991): Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? In Barnes CD, Pompeiano O (eds). "Progress in Brain Research. Vol 88, Neurobiology of the Locus Coeruleus." Amsterdam: Elsevier Biomedical Press, pp 257-268.
15. Fritschy J-M, Grzanna R (1992): Degeneration of rat locus coeruleus neurons is not accompanied by an irreversible loss of ascending projections. Evidence for re-establishment of forebrain innervation by surviving neurons. Ann N Y Acad Sci 648:275-278
16. Fritschy J-M, Geffard M, Grzanna R (1990): The response of noradrenergic axons to systematically administered DSP-4 in the rat: an immunohistochemical study using antibodies to noradrenaline and dopamine-β-hydroxylase. J Chem Neuroanat 3:309-321.
17. Grzanna R, Berger U, Fritschy J-M, Geffard M (1989): Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J Histochem Cytochem 37:1435-1442.
18. Hallman H, Jonsson G (1984): Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons. Eur J Pharmacol 103:269-278.
19. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G (1985): Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem 44:117-127.
20. Hökfelt T, Johansson O, Goldstein M (1984): Central catecholamine neurons as revealed by immunohistochemistry with special reference to adrenaline neurons. In Bjorklund A, Hökfelt T (eds): "Handbook of Chemical Neuroanatomy. Vol 2, Classical Transmitters in the CNS, Part I." Amsterdam: Elsevier Biomedical Press, pp 157-276.
21. Hsu S-M, Raind L, Fanger H (1981): Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique. J Histochem Cytochem 29:577-580.
22. Iversen LL, Rossor MN, Reynolds GP, Hills R, Roth M, Mountjoy CQ, Foote SL, Morrison JH, Bloom FE (1983): Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neuroscience 39:95-100.
23. Jaim-Etcheverry G, Zeiher LM (1980): DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res 188:513-523.
24. Jaim-Etcheverry G, Zeiher LM (1983): 2-Chloroethylamines: new chemical tools for the study of noradrenergic neurons. Trends Pharmacol Sci 4:473-475.
25. Jonsson G (1983): Chemical lesioning techniques: monoamine neurotoxin. In Bjorklund A, Hokfelt T (eds): "Handbook of Chemical Neuroanatomy Vol 1: Methods in Chemical Neuroanatomy." New York: Elsevier Press, pp 463-507.
26. Jonsson G, Hallman H, Ponzio F, Ross SB (1981): DSP-4 (N-2-chloroethyl-N-ethyl-2-bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol 72:173-188.
27. 3H-DSP-4, a noradrenaline neurotoxin, in central and peripheral noradrenaline neurons. J Neurochem 44:S184.
28. 3H] desipramine binding associated with neuronal noradrenaline uptake sites in rat brain membranes. J Neurosci 2:1515-1525.
29. Loughlin SE, Foote SL, Bloom FE (1986a): Efferent projections of nucleus locus coeruleus: topographic organization of cells of origin demonstrated by three-dimensional reconstruction Neuroscience 18:291-306.
30. Loughlin SE, Foote SL, Bloom FE (1986b): Efferent projections of nucleus locus coeruleus: morphological subpopulations have different targets. Neuroscience 18:307-319.
31. Mann DMA, Lincoln J, Yates PO (1980): Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiatry 136:533-541.
32. Marcyniuk B, Mann DMA, Yates PO (1986): The topography of cell loss from locus coeruleus in Alzheimer's disease. J Neurol Sci 76:335-345.
33. Moore RY, Card JP (1984): Noradrenaline-containing neuron system. In Bjorklund A, Hökfelt T (eds): "Handbook of Chemical Neuroanatomy. Vol 2: Classic Transmitters in the CNS, Part 1." Amsterdam: Elsevier Biomedical Press, pp 123-156.
34. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1992): Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42:339-343.
35. The Parkinson Study Group (1989): Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1363-1371.
36. The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183.
37. Paxinos G (1985): "The Rat Nervous System. Vol 1, Forebrain and Midbrain." Sydney: Academic Press.
38. Paxinos G, Watson C (1986): "The Rat Brain in Stereotaxic Coordinates." Sydney: Academic Press.
39. Riekkinen Jr P, Riekkinen M, Valjiakka A, Riekkinen P, Sirvio J (1992): DSP-4, a noradrenergic neurotoxin, produces more severe biochemical and functional deficits in aged than young rats. Brain Res 570:293-299.
40. Ross SB (1976): Long-term effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br J Pharmacol 58:521-527.
41. Ross SB (1987): Pharmacological and toxicological exploitation of amine transporters. Trends Pharmacol Sci 8:227-231.
42. Ross SB, Renyi AL (1976): On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of noradrenaline. J Pharm Pharmacol 248:458-459.
43. Ross SB, Johansson JG, Lindborg B, Dahlbom R (1973): Cyclyzing compounds. I. Tertiary N-(2-bromobenzyl)-N-haloalkylamine with adrenergic blocking actions. Acta Pharm Suec 10:29-42.
44. Salo FT, Tatton WG (1992): Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394-400.
45. Strolin-Benedetti M, Keane PE (1980): Differential changes in monoamine oxidase A and B activity in ageing rat brain. J Neurochem 35:1026-1032.
46. Swanson LB, Hartman BK (1975): The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-β-hydroxylase as a marker. J Comp Neurol 163:467-506.
47. Tetrad JW, Langston JW (1989): The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
48. Van Dongen PAM (1981): The human locus coeruleus in neurology and psychiatry (Parkinson's, Lewy body, Hallervorden-Spatz, Alzheimer's and Korsakoff's disease, (pre)senile dementia, schizophrenia, affective disorders, psychosis). Prog Neurobiol 17:97-139.
49. Vijayashankar N, Brody H (1979): A quantitative study of the pigmental neurons in the nuclei locus coeruleus and sub-coeruleus in man as related to aging. J Neuropathol Exp Neurol 38:490-497.
50. + in vivo. Eur J Pharmacol 243:241-247.
51. Yu PH, Davis BA, Boulton AA (1992): Aliphatic propargylamines: potent selective irreversible monoamine oxidase-B inhibitors. J Med Chem 35:3705-3713.
52. Yu PH, Davis BA, Boulton AA (1994a): Neurochemical and neuroprotective effects of some aliphatic propargylamine MAO-B inhibitors: new selective nonamphetamine-like monoamine oxidase B inhibitors. J Neurochem 62:697-704.
53. Yu PH, Davis BA, Fang J, Boulton AA (1994b): Neuroprotective effect of different monoamine oxidase-B inhibitors against DSP-4 induced noradrenaline depletion in mouse hippocampus. J Neurochem 63:1820-1828.
54. Zaczek R, Fritschy J-M, Culp S, De Souza EB, Grzanna R (1991): Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites. Brain Res 522:308-314.